CTMX: CytomX Therapeutics, Inc.
Performance
CTMX -45.30%
Watchlist
Select an item
Summary
CTMX at a glance
CTMX returned -45.30% over the past year and -21.35% a year over five years. Its worst drop in that year was -70.67%, smaller than 5% of stocks on Redstone, and its Sharpe ratio of -0.33 beats 15% of stocks on Redstone. It pays no dividends.
Current Drawdown
-70.67%
Rolling Volatility
81.65%
Actions
Metrics
Risk Indicators
Alpha-45.53%
Beta1.69x
Sharpe-0.33
Sortino-0.54
Omega0.94
Calmar-0.64
Martin-0.70
Profile
About CTMX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $431M
- Listed
- Oct 2015
- Employees
- 69
- Headquarters
- South San Francisco, CA
- Website
- cytomx.com
Comparisons